Silvercrest Asset Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Silvercrest Asset Management’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-176,125	Closed	-$2.3M	–	824
2022 Q3	$2.3M	Sell	176,125 -4,797	-3%	-$72.6K	0.02%	429
2022 Q2	$2.32M	Sell	180,922 -8,083	-4%	-$112K	0.02%	447
2022 Q1	$2.88M	Buy	189,005 +1,762	+0.9%	+$27.5K	0.02%	448
2021 Q4	$3.32M	Hold	187,243	–	–	0.02%	426
2021 Q3	$3.94M	Buy	187,243 +70,981	+61%	+$1.56M	0.03%	409
2021 Q2	$2.29M	Buy	116,262 +61,920	+114%	+$1.45M	0.02%	483
2021 Q1	$1.58M	Buy	+54,342	New	+$1.52M	0.01%	514

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Silvercrest Asset Management's NGM Position: Q4 2022 in Review

Silvercrest Asset Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2022, closing a stake of 176,125 shares — an estimated $2.3M sold.

Silvercrest Asset Management first reported a position in NGM in Q1 2021 and held it in 7 quarters. The position peaked at $3.94M in Q3 2021. 125 funds tracked by Wall St. Rank hold NGM as of Q4 2022.

Silvercrest Asset Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Silvercrest Asset Management sold 176,125 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $2.3M.
Silvercrest Asset Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
Silvercrest Asset Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $3.94M in Q3 2021.
125 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Silvercrest Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.